STOCK TITAN

Aura Biosciences grants COO 265K options, 135K RSUs

Aura COO Susan Abu‑Absi received inducement RSUs and stock options that vest over years, including RSUs starting Sept. 15, 2027 and options beginning Aug. 10, 2027.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aura Biosciences, Inc. (AURA) reported that Chief Operating Officer Susan Abu‑Absi received equity awards on 2026-09-01. She was granted 265,487 stock options with an exercise price of $7.43 per share, expiring on 2036-09-01, and 134,513 RSUs as an inducement award. The RSUs vest in four substantially equal annual installments starting on September 15, 2027, and the options vest 25% on August 10, 2027 with the remainder vesting pro rata in 36 monthly installments, in each case subject to continued service.

Positive

  • None.

Negative

  • None.
Insider Abu-Absi Susan
Role Chief Operating Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F2 265,487 $0.00 $0.00
Grant/Award Common Stock F1 134,513 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 265,487 contracts (Direct); Common Stock — 134,513 shares (Direct)
Footnotes (2)
  1. F1. These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement with the Issuer. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments, subject to the Reporting Person's continued service as of the relevant vesting date, with the first tranche scheduled to vest on September 15, 2027.
  2. F2. The option shall vest as follows: 25% of the options vest on August 10, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
RSUs granted 134,513 RSUs Inducement award to COO Susan Abu-Absi on 2026-09-01
Stock options granted 265,487 options Grant to COO Susan Abu-Absi on 2026-09-01
Option exercise price $7.43 per share Exercise price for 265,487 stock options
Option expiration date 2036-09-01 Expiration of stock options granted on 2026-09-01
RSU vesting start date September 15, 2027 First of four substantially equal annual RSU vesting dates
Initial option vesting 25% on August 10, 2027 First vesting tranche of stock options
Remaining option vesting period 36 monthly installments Remaining options vest pro rata after initial 25% tranche
restricted stock unit ("RSU") financial
"These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement"
inducement award financial
"These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement"
An inducement award is a special cash or equity payment given to a new hire—often an executive or key employee—outside the company’s regular pay plans to persuade them to join. Think of it like a signing bonus that can align the new person’s goals with shareholders but also represents a cost and can reduce existing owners’ percentage of the company, so investors watch these awards for their impact on ownership and future performance.
vesting financial
"These RSUs vest in four substantially equal annual installments, subject to the Reporting Person's continued service"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
stock option financial
"The option shall vest as follows: 25% of the options vest on August 10, 2027"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "7.4300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

What equity awards did AURA grant to COO Susan Abu-Absi on 2026-09-01?

On 2026-09-01, Susan Abu-Absi received 134,513 RSUs and 265,487 stock options in Aura Biosciences, Inc. The options have an exercise price of $7.43 per share and an expiration date of 2036-09-01, all held as direct ownership.

What is the vesting schedule for the new RSUs granted by AURA (AURA)?

The 134,513 RSUs granted as an inducement award vest in four substantially equal annual installments, subject to Susan Abu-Absi’s continued service, with the first tranche scheduled to vest on September 15, 2027.

How do the newly granted AURA stock options to the COO vest?

The 265,487 stock options vest as follows: 25% vest on August 10, 2027, and the remaining 75% vest pro rata in 36 monthly installments thereafter, subject to continued service on each vesting date.

What is the exercise price and expiration date of the AURA options granted?

The options granted to Susan Abu-Absi have an exercise price of $7.43 per share and an expiration date of 2036-09-01. Each option is a right to buy one share of Aura Biosciences, Inc. common stock upon vesting and exercise.

How many AURA shares does the COO directly hold after these transactions?

Following these awards, Susan Abu-Absi directly holds 134,513 shares of common stock from the RSUs and 265,487 stock options representing rights to acquire the same number of common shares, as reported in the Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Abu-Absi Susan

(Last)(First)(Middle)
C/O AURA BIOSCIENCES, INC.
80 GUEST STREET

(Street)
BOSTON MASSACHUSETTS 02135

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/01/2026A134,513(1)A$0134,513D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$7.4309/01/2026A265,487 (2)09/01/2036Common Stock265,487$0265,487D
Explanation of Responses:
1. These securities represent an inducement award granted pursuant to a restricted stock unit ("RSU") award agreement with the Issuer. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments, subject to the Reporting Person's continued service as of the relevant vesting date, with the first tranche scheduled to vest on September 15, 2027.
2. The option shall vest as follows: 25% of the options vest on August 10, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
/s/ Amy Elazzouzi, as Attorney-in-Fact09/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)